Zoledronic acid

Drug Profile

Zoledronic acid

Alternative Names: Aclasta; AK-156; CGP-42446A; Reclast; ZOL-446; zoledronate; Zometa

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Asahi Kasei Pharma Corp; Novartis; UNICANCER
  • Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Geranyltranstransferase inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Bone metastases; Corticosteroid-induced osteoporosis; Fracture; Male osteoporosis; Malignant hypercalcaemia; Mesothelioma; Multiple myeloma; Osteitis deformans; Postmenopausal osteoporosis
  • Registered Osteoporosis
  • Phase II Breast cancer
  • Discontinued Osteogenesis imperfecta; Osteosarcoma; Rheumatoid arthritis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 05 Mar 2018 Novartis Pharmaceuticals completes a phase III trial in Corticosteroid-induced osteoporosis (In adolescents, In children) Australia, Canada, Finland, Romania, Italy, Russia, South Africa, Germany, Hungary, Belgium, Poland and the UK (IV) (EudraCT2008-001252-52) (NCT00799266)
  • 07 Nov 2017 Asahi Kasei Pharma Corporation completes a clinical trial for Osteoporosis in Japan (UMIN000026507)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top